Hemogenyx surges 19% on US manufacturing deal for leukaemia therapy

Shares in Hemogenyx Pharmaceuticals PLC surged 19% after the company announced a manufacturing partnership with US-based Made Scientific to scale up production of its experimental CAR-T leukaemia therapy, HG-CT-1. This collaboration is expected to accelerate Hemogenyx's ongoing Phase I clinical trials and could support the inclusion of paediatric patients, building on encouraging early safety and efficacy signals for the treatment.

Analysis

Hemogenyx Pharmaceuticals (LSE:HEMO) experienced a significant 19% share price increase to 900p following the announcement of a strategic manufacturing agreement with Made Scientific. This partnership is a critical operational milestone for the company’s experimental CAR-T therapy, HG-CT-1, which targets relapsed or treatment-resistant acute myeloid leukaemia. By securing a US-based specialist for cell therapy production, Hemogenyx not only facilitates the scaling of its manufacturing process but also de-risks a crucial part of the supply chain for both ongoing clinical trials and potential future commercialization. The agreement is expected to directly accelerate the current Phase I trial and introduces the possibility of expanding cohorts to include paediatric patients, broadening the therapy's potential market. This development, combined with the company's report of encouraging early safety and efficacy signals, provides tangible validation for the asset's progress and underpins the market's strongly positive reaction.

Key Decisions for Investors

• Investors should view the manufacturing partnership as a significant de-risking event for the HG-CT-1 program, which could accelerate the development timeline and positively impact valuation models.
• While the operational progress is a clear positive, it is crucial to remember that HG-CT-1 remains in a high-risk, early-stage Phase I trial, and investment theses must account for the binary outcomes typical of biotech drug development.
• Monitor future catalysts closely, including the release of more substantive Phase I trial data, updates on patient enrollment speed, and any formal initiation of a paediatric cohort, as these will be the next key indicators of the therapy's viability.